


Supplemental material to:


Jun Okamura, Yiping Huang, David Moon, Mariana Brait, Xiaofei Chang, Myoung Sook Kim. Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer. *Cancer Biol Ther* 13(3); DOI: 10.4161/cbt.13.3.18695

<http://www.landesbioscience.com/journals/cbt/article/18695/>

## Supplemental Information



**Figure S1.** Average values of  $2^{-\Delta C_t}$  ( $2^{-\Delta C_t}$ ,  $\Delta C_t = C_{t,IGFBP7} - C_{t,\beta\text{-actin}}$ ) in tissues and cell lines were calculated from levels of IGFBP7 relative to  $\beta$ -actin based on the threshold cycle ( $C_t$ ) in each group of lung tissues and CP-S and CP-R cell lines. Values indicate mean  $\pm$  SD. Two graphs were derived from the same graph with only difference in  $2^{-\Delta C_t}$  values ranging from 0 to 60 (upper) and from 0 to 4 (Lower). A line in upper graph indicates 4 as a  $2^{-\Delta C_t}$  value.



**Figure S2. Increased sensitivity to cisplatin by rIGFBP7 in the resistant cell lines.** Left panels, rIGFBP7 alone (100 ng/ml) had a negligible effect on cell growth in PC-9/CP (A) and PC-14/CP cell lines (B). Middle panels, PC-9/CP and PC-14/CP cells were co-treated with rIGFBP7 (100 ng/ml) and cisplatin (0 ~ 50  $\mu\text{g/ml}$ ) for 48 hrs, and cellular sensitivity to cisplatin was determined by MTT assay. Right panels, Cells were treated with cisplatin at IC50 (30  $\mu\text{g/ml}$ ) for three days in the presence of rIGFBP7, and cell growth was assessed by MTT assay (Right). Experiments were done in duplicate, and values indicate means  $\pm$  SD. \*,  $P < 0.05$  in *T*-test.